ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 313,56
-0,57%
Dow Jones
42 690,17
-0,70%
DAX
19 909,14
-0,25%
Brent Oil
74,455
1,13%
Bitcoin
92 774,97
-0,80%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BioMarin Pharmaceutical Inc (BMRN)

  7. BioMarin Pharmaceutical Inc (BMRN) Actualités

BMRN

BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BMRN
DateHeureSourceTitreSymboleSociété
04/12/202400h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
16/11/202416h45PR Newswire (US)BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024NASDAQ:BMRNBioMarin Pharmaceutical Inc
12/11/202420h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
06/11/202414h00PR Newswire (US)BioMarin to Participate in Three Upcoming Investor ConferencesNASDAQ:BMRNBioMarin Pharmaceutical Inc
31/10/202420h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMRNBioMarin Pharmaceutical Inc
29/10/202421h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/10/202421h03PR Newswire (US)BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and OutlookNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/10/202413h00GlobeNewswire Inc.Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug CandidateNASDAQ:BMRNBioMarin Pharmaceutical Inc
16/10/202414h30PR Newswire (US)BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
01/10/202422h50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
30/09/202422h29Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:BMRNBioMarin Pharmaceutical Inc
18/09/202414h00PR Newswire (US)BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/09/202419h00PR Newswire (US)BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial GuidanceNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/09/202413h30PR Newswire (US)BioMarin to Host Investor Day Today at 10:30 a.m. Eastern TimeNASDAQ:BMRNBioMarin Pharmaceutical Inc
29/08/202414h00PR Newswire (US)BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NYNASDAQ:BMRNBioMarin Pharmaceutical Inc
21/08/202414h30PR Newswire (US)BioMarin Announces New R&D and Business Development LeadershipNASDAQ:BMRNBioMarin Pharmaceutical Inc
19/08/202415h00PR Newswire (US)BioMarin to Host 2024 Investor Day on September 4th in New YorkNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/08/202422h03PR Newswire (US)BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 GuidanceNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/08/202422h01PR Newswire (US)BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and ItalyNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/07/202422h05PR Newswire (US)U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 DiseaseNASDAQ:BMRNBioMarin Pharmaceutical Inc
23/07/202414h00PR Newswire (US)BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
17/06/202414h30PR Newswire (US)BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone HealthNASDAQ:BMRNBioMarin Pharmaceutical Inc
08/06/202400h09PR Newswire (US)KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600NASDAQ:BMRNBioMarin Pharmaceutical Inc
07/06/202415h00PR Newswire (US)BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 CongressNASDAQ:BMRNBioMarin Pharmaceutical Inc
08/05/202414h00PR Newswire (US)BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NVNASDAQ:BMRNBioMarin Pharmaceutical Inc
04/05/202422h00PR Newswire (US)New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
24/04/202422h03PR Newswire (US)BioMarin Reports Record Financial Results for the First Quarter 2024NASDAQ:BMRNBioMarin Pharmaceutical Inc
10/04/202414h00PR Newswire (US)BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ETNASDAQ:BMRNBioMarin Pharmaceutical Inc
12/03/202413h30PR Newswire (US)New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingNASDAQ:BMRNBioMarin Pharmaceutical Inc
07/03/202414h30PR Newswire (US)BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial OfficerNASDAQ:BMRNBioMarin Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:BMRN

Dernières Valeurs Consultées

AQSE
SHEP
Shepherd Neame
LSE
52LN
Sthn.pac.42a1ca
BIT
S29352
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés